Patent Term Extension Application for TEVIMBRA® (tislelizumab-jsgr), Patent No. 8,735,553
🏛 Food and Drug Administration (FDA)FDA-2024-E-3572
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.